KAI1蛋白在子宫内膜癌中的表达及其临床意义

目的:研究KAI1蛋白在子宫内膜癌组织中的表达及其与临床病理参数的关系.方法:采用免疫组织化学EnVision二步法检测76例子宫内膜癌、15例不典型增生子宫内膜、20例正常增生期子宫内膜组织中KAI1蛋白的表达情况,对检测结果与子宫内膜癌的临床病理参数及预后关系作统计学分析.结果:KAI1蛋白在子宫内膜癌的阳性表达低于不典型增生内膜和正常增生期子宫内膜,差异有统计学意义.KAI1蛋白在子宫内膜癌的表达与组织学分级、肌层浸润程度呈负相关,差异有统计学意义.KAI1表达阴性的患者术后生存期更短.结论:KAI1蛋白在子宫内膜癌的进展过程中表达降低.KAI1蛋白的检测可能成为监测子宫内膜癌进展及临床判断预后有价值的生物学指标.

Expression of KAI1 protein in endometrial carcinoma and its clinical significance

Objective:To investigate the expression of KAI1 protein and its correlations with the clinicopathological parameters of endometrial carcinoma. Methods: Immunohistochemical staining (EnVision method) was used to detect the expression of KAI1 protein in 76 cases of endometrial carcinoma, 15 cases of uterine atypical endometrial hyperplasia and 20 cases of normal proliferative phase endometrium. Correlations of expression of KAI1 in endometrial carcinoma with clinicopathological parameters and prognosis were statistically analyzed. Results: Compared with ormal proliferative phase endometrium and atypical endometrial hyperplasia, the expression of KAI1 in endometrial carcinoma was significantly decreased. In addition, the expression of KAI1 was negative correlated with histological grade and depth of myometrial invasion. It was also found that loss of KAI1 expression was correlated closely with poor survival. Conclusion: KAI1 is down-regulated in the malignant progression of endometrial carcinoma. Clinically it may be a useful indicator of the tumor progression and may provide prognostic information on the outcome of this disease.